CD274 and neoplasm: Several biomarkers have been reported to predict immunotherapy response, including programmed death ligand 1 (PD‐L1), microsatellite instability (MSI), tumor mutational load (TML), and tumor‐infiltrating lymphocytes, among others.8, 9, 10